Long-term forgetting in preclinical Alzheimer's disease
Alzheimer's disease is characterised by progressive pathophysiological changes that correspond roughly to preclinical (ie, cognitively unimpaired), mild cognitive impairment, and dementia stages.
1 Biomarkers continue to be developed, tested, and used to detect and track the pathophysiological manifestations of this disease. Although neuropsychological tests, clinical ratings, and composite cognitive test scores have shown initial promise, 2-5 the field would benefit from additional ways to detect and track cognitive, behavioural, and functional manifestations of Alzheimer's disease with optimal power, ease, and availability, particularly in the preclinical and early clinical stages.
In this issue of The Lancet Neurology, Philip Weston and colleagues 6 show the promise of a baseline and 7-day follow-up assessment strategy to measure accelerated long-term forgetting in presymptomatic Alzheimer's disease. 35 cognitively unimpaired autosomal dominant Alzheimer's disease mutation carriers and non-carriers were studied on average 7 years before their affected parents' age at symptom onset. Standard 15-item word list, short story, and complex figure learning and recall memory tests were done during an initial in-person assessment. Recall and recognition memory tests were done during a 7-day follow-up telephone call. Although the groups did not differ in their learning or 30-min recall memory scores, carriers did less well in measures of recall and recognition memory 7 days later. 7-day forgetting was associated with subjective memory concerns and proximity to age at symptom onset in the carriers. On the basis of these findings, the authors suggest that accelerated long-term forgetting might provide a more sensitive indicator of cognitive decline than do standard learning or 30-min memory tests in presymptomatic Alzheimer's disease; they suggest that accelerated long-term forgetting reflects an early decline in mediated memory consolidation and associated Alzheimer's disease pathology in the hippocampus, contributes to some of the earliest subjective memory concerns in at-risk persons, and has the potential to help evaluate preclinical treatments. 6 Additional research is needed, not only to confirm the study findings in the presymptomatic stages of autosomal dominant early-onset Alzheimer's disease, but also to show generalisability to the preclinical stages of late-onset disease and to consider how these results might be affected by ageing and other age-related disorders. Additional studies are also needed to clarify the extent to which accelerated long-term forgetting is related to biomarker measurements of amyloid burden, tau, and neurodegenerative pathology, other preclinical cognitive changes, and subsequent clinical progression. Refinements in the long-term forgetting framework might be needed to extend the findings of this study to later Alzheimer's disease stages, account for any initial learning and memory declines, minimise potentially confounding rehearsal and learning effects associated with longitudinal assessments, and provide an indicator of progressive cognitive decline that could be used as an endpoint in preclinical trials. Refinements to the framework might also be needed to minimise participant burden in longitudinal studies and preclinical Alzheimer's disease trials and support the study of long-term forgetting in observational studies and therapeutic trials.
Interest in use of mobile and other digital technologies to detect and track cognitive, behavioural, and functional changes with greater ease, real-world value, and statistical power is growing, and there could be a chance to leverage these technologies in assessment of long-term forgetting. 7 This elegant study illustrates the opportunity now at hand to develop, test, and use new methods to detect and track the earliest cognitive changes associated with Alzheimer's disease, monitor a person's risk, and help evaluate promising prevention therapies.
The field of multiple sclerosis has undergone astounding changes over the past three decades. Many developments are the result of MRI, which has improved multiple sclerosis diagnosis and enhanced clinical trial outcome measures. The term clinically isolated syndrome describes a first symptomatic episode of CNS demyelination that might later develop into multiple sclerosis. Improving the imaging criteria to predict conversion to clinically definite multiple sclerosis has been a major, collaborative research effort. The MAGNIMS network now add to this improvement process with publication of their latest results in The Lancet Neurology.
1
In the late 1990s, Barkhof and colleagues 2 studied 74 patients with a clinically isolated syndrome for MRI predictors of clinically definite multiple sclerosis. They found that, unless a gadolinium-enhancing lesion was present, nine or more T2-weighted lesions (including three or more periventricular lesions in addition to juxtacortical and infratentorial lesions) provided high sensitivity and specificity for future clinically definite multiple sclerosis.
2 These criteria had an accuracy of 80% and predicted conversion to clinically definite multiple sclerosis better than previous models. The initial set of McDonald multiple sclerosis diagnostic criteria, 3 published in 2001, were notable because MRI lesions could, for the first time, serve as surrogates for clinical relapses. Subsequent revisions further simplified the McDonald MRI criteria while remaining predictive of conversion to clinically definite multiple sclerosis. 4 By the time the 2010 McDonald criteria were introduced, the criterion of dissemination in space (DIS) could be met by two lesions in characteristic locations, and dissemination in time (DIT) could be met with a single MRI scan showing the simultaneous presence of an asymptomatic gadolinium-enhancing lesion and one or more non-enhancing lesions. As multiple sclerosis diagnosis has evolved, the revisions to diagnostic criteria have increased sensitivity, which has aided earlier diagnosis. The study reported here showed that for both sets of MRI criteria, sensitivity was greater than specificity for predicting clinically definite multiple sclerosis.
1 Although high sensitivity is a benefit, the modest specificity should give one pause. One study 7 pointed out the importance of not misdiagnosing other CNS diseases as multiple sclerosis. In that study at four academic medical centres, 110 people seen over a period of less than 1·5 years were found to have been misdiagnosed. 70% of the 110 individuals had received disease-modifying therapy
